Rekova, Petra
Kovarova, Ivana
Uher, Tomas
Srpova, Barbora
Dostalova, Gabriela
Linhart, Ales
Vaneckova, Manuela
Stastna, Dominika http://orcid.org/0000-0003-2418-4847
Funding for this research was provided by:
Všeobecná Fakultní Nemocnice v Praze (MH CZ-DRO-VFN64165, MH CZ-DRO-VFN64165, MH CZ-DRO-VFN64165)
Ministerstvo Zdravotnictví Ceské Republiky (NU22-04-00193)
Charles University
Article History
Received: 11 April 2023
Accepted: 11 July 2023
First Online: 22 July 2023
Declarations
:
: The study was approved by the Ethics Committee of the General University Hospital in Prague and complied with the Declaration of Helsinki and good clinical practice guidelines. All patients gave written informed consent to the study, including the genetic analyses.
: All patients gave written informed consent to the study, including the genetic analyses.
: PR was a consultant for Takeda Pharmaceuticals. She received speaker honoraria from Takeda Pharmaceuticals and Sanofi-Genzyme, travel and accommodation support, and symposium reimbursement from Takeda Pharmaceuticals. IK received financial support for conference travel from Novartis, Teva, Merck, and Roche. TU received financial support for conference travel from Biogen, Novartis, Sanofi, Roche, and Merck and speaker honoraria from Biogen, Novartis, and Roche, as well as support for research activities from Biogen and Sanofi. BS received compensation for travelling and conference fees from Novartis, Sanofi, Biogen, Roche, and Merck, as well as support for research activities from Biogen. AL received consultation and speaker honoraria from Takeda, Amicus, and Sanofi and holds a position on the Fabry registry board and the Amicus FollowME registry board. GD has no relevant conflicts of interest to declare. MV received compensation for travelling, speaker honoraria, and consultant fees from Biogen, Novartis, Roche, Merck, and Teva. DS received financial support for conference travel and/or speaker honoraria from Novartis, Biogen, Merck, Teva, Janssen-Cilag, and Roche.